Cargando…

Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study

BACKGROUND: SARS-CoV-2 remains a world-wide health issue. SARS-CoV-2-specific immunity is induced upon both infection and vaccination. However, defining the long-term immune trajectory, especially after infection, is limited. In this study, we aimed to further the understanding of long-term SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales: Hvidt, Astrid Korning, Guo, Huaijian, Andersen, Rebecca, Lende, Stine Sofie Frank, Vibholm, Line Khalidan, Søgaard, Ole Schmeltz, Schleimann, Marianne Hoegsbjerg, Russell, Victoria, Cheung, Angela Man-Wei, Paramithiotis, Eustache, Olesen, Rikke, Tolstrup, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652616/
https://www.ncbi.nlm.nih.gov/pubmed/37974069
http://dx.doi.org/10.1186/s12865-023-00583-y
_version_ 1785147722721918976
author Hvidt, Astrid Korning
Guo, Huaijian
Andersen, Rebecca
Lende, Stine Sofie Frank
Vibholm, Line Khalidan
Søgaard, Ole Schmeltz
Schleimann, Marianne Hoegsbjerg
Russell, Victoria
Cheung, Angela Man-Wei
Paramithiotis, Eustache
Olesen, Rikke
Tolstrup, Martin
author_facet Hvidt, Astrid Korning
Guo, Huaijian
Andersen, Rebecca
Lende, Stine Sofie Frank
Vibholm, Line Khalidan
Søgaard, Ole Schmeltz
Schleimann, Marianne Hoegsbjerg
Russell, Victoria
Cheung, Angela Man-Wei
Paramithiotis, Eustache
Olesen, Rikke
Tolstrup, Martin
author_sort Hvidt, Astrid Korning
collection PubMed
description BACKGROUND: SARS-CoV-2 remains a world-wide health issue. SARS-CoV-2-specific immunity is induced upon both infection and vaccination. However, defining the long-term immune trajectory, especially after infection, is limited. In this study, we aimed to further the understanding of long-term SARS-CoV-2-specific immune response after infection. RESULTS: We conducted a longitudinal cohort study among 93 SARS-CoV-2 recovered individuals. Immune responses were continuously monitored for up to 20 months after infection. The humoral responses were quantified by Spike- and Nucleocapsid-specific IgG levels. T cell responses to Spike- and non-Spike epitopes were examined using both intercellular cytokine staining (ICS) assay and Activation-Induced marker (AIM) assay with quantification of antigen-specific IFNγ production. During the 20 months follow-up period, Nucleocapsid-specific antibody levels and non-Spike-specific CD4 + and CD8 + T cell frequencies decreased in the blood. However, a majority of participants maintained a durable immune responses 20 months after infection: 59% of the participants were seropositive for Nucleocapsid-specific IgG, and more than 70% had persisting non-Spike-specific T cells. The Spike-specific response initially decreased but as participants were vaccinated against COVID-19, Spike-specific IgG levels and T cell frequencies were boosted reaching similar or higher levels compared to 1 month post-infection. The trajectory of infection-induced SARS-CoV-2-specific immunity decreases, but for the majority of participants it persists beyond 20 months. The T cell response displays a greater durability. Vaccination boosts Spike-specific immune responses to similar or higher levels as seen after primary infection. CONCLUSIONS: For most participants, the response persists 20 months after infection, and the cellular response appears to be more long-lived compared to the circulating antibody levels. Vaccination boosts the S-specific response but does not affect the non-S-specific response. Together, these findings support the understanding of immune contraction, and with studies showing the immune levels required for protection, adds to the knowledge of durability of protection against future SARS-CoV-2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12865-023-00583-y.
format Online
Article
Text
id pubmed-10652616
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106526162023-11-16 Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study Hvidt, Astrid Korning Guo, Huaijian Andersen, Rebecca Lende, Stine Sofie Frank Vibholm, Line Khalidan Søgaard, Ole Schmeltz Schleimann, Marianne Hoegsbjerg Russell, Victoria Cheung, Angela Man-Wei Paramithiotis, Eustache Olesen, Rikke Tolstrup, Martin BMC Immunol Research BACKGROUND: SARS-CoV-2 remains a world-wide health issue. SARS-CoV-2-specific immunity is induced upon both infection and vaccination. However, defining the long-term immune trajectory, especially after infection, is limited. In this study, we aimed to further the understanding of long-term SARS-CoV-2-specific immune response after infection. RESULTS: We conducted a longitudinal cohort study among 93 SARS-CoV-2 recovered individuals. Immune responses were continuously monitored for up to 20 months after infection. The humoral responses were quantified by Spike- and Nucleocapsid-specific IgG levels. T cell responses to Spike- and non-Spike epitopes were examined using both intercellular cytokine staining (ICS) assay and Activation-Induced marker (AIM) assay with quantification of antigen-specific IFNγ production. During the 20 months follow-up period, Nucleocapsid-specific antibody levels and non-Spike-specific CD4 + and CD8 + T cell frequencies decreased in the blood. However, a majority of participants maintained a durable immune responses 20 months after infection: 59% of the participants were seropositive for Nucleocapsid-specific IgG, and more than 70% had persisting non-Spike-specific T cells. The Spike-specific response initially decreased but as participants were vaccinated against COVID-19, Spike-specific IgG levels and T cell frequencies were boosted reaching similar or higher levels compared to 1 month post-infection. The trajectory of infection-induced SARS-CoV-2-specific immunity decreases, but for the majority of participants it persists beyond 20 months. The T cell response displays a greater durability. Vaccination boosts Spike-specific immune responses to similar or higher levels as seen after primary infection. CONCLUSIONS: For most participants, the response persists 20 months after infection, and the cellular response appears to be more long-lived compared to the circulating antibody levels. Vaccination boosts the S-specific response but does not affect the non-S-specific response. Together, these findings support the understanding of immune contraction, and with studies showing the immune levels required for protection, adds to the knowledge of durability of protection against future SARS-CoV-2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12865-023-00583-y. BioMed Central 2023-11-16 /pmc/articles/PMC10652616/ /pubmed/37974069 http://dx.doi.org/10.1186/s12865-023-00583-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hvidt, Astrid Korning
Guo, Huaijian
Andersen, Rebecca
Lende, Stine Sofie Frank
Vibholm, Line Khalidan
Søgaard, Ole Schmeltz
Schleimann, Marianne Hoegsbjerg
Russell, Victoria
Cheung, Angela Man-Wei
Paramithiotis, Eustache
Olesen, Rikke
Tolstrup, Martin
Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
title Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
title_full Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
title_fullStr Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
title_full_unstemmed Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
title_short Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
title_sort long-term humoral and cellular immunity after primary sars-cov-2 infection: a 20-month longitudinal study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652616/
https://www.ncbi.nlm.nih.gov/pubmed/37974069
http://dx.doi.org/10.1186/s12865-023-00583-y
work_keys_str_mv AT hvidtastridkorning longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT guohuaijian longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT andersenrebecca longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT lendestinesofiefrank longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT vibholmlinekhalidan longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT søgaardoleschmeltz longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT schleimannmariannehoegsbjerg longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT russellvictoria longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT cheungangelamanwei longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT paramithiotiseustache longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT olesenrikke longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy
AT tolstrupmartin longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy